Literature DB >> 7502532

The knife or the pill in the long-term treatment of gastroesophageal reflux disease?

L R Lundell1.   

Abstract

Gastroesophageal reflux disease (GERD) is a common condition, and it is now generally recognized that modern medical therapy allows the physician to both heal the esophagitis and relieve the patients from troublesome symptoms such as heartburn, acid regurgitation and disabling chest pain. In addition, long-term therapy with potent acid inhibitory drugs can maintain these patients in clinical remission. The indications for antireflux surgery and long-term medical therapy have developed and changed with time but are today essentially similar, and in fact, it can be hypothesized that the outcome of a short-term "therapeutic trials" with the proton pump inhibitor would be a useful clinical tool, not only as a diagnostic test for the disease but also in the selection process before referring the patient to antireflux surgery. Antireflux surgery is designed to improve the function of the antireflux barrier by reconstructing the physiology of the gastroesophageal junction. Studies have shown that a fundoplication procedure improves the strength and length of the lower esophageal sphincter and also restitutes the flutter valve mechanism. However, since gastroesophageal reflux disease is a common disorder, it is impossible for every patient to be attended by an expert surgeon, and this might be one important reason for the sometimes poor results presented after surgical treatment. When the question arises about which type of long-term therapy should be chosen in each clinical situation, this situation should also partly be influenced by some epidemiological information. If we assume that we expose a hypothetical group of 100 patients with symptomatic, chronic severe reflux disease, also presenting endoscopic evidence of esophagitis of varying severity, available clinical information would suggest that only 25 can be considered suitable for antireflux surgery, depending on the frequently associated complicating medical disorders and the age distribution of the actual patient population. Therefore, it deserves to be emphasized that the majority of patients with complicated reflux disease are not fit for surgery and should consequently be managed medically. For younger patients with disabling GERD, antireflux surgery is still the gold standard and obviously very cost effective.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7502532      PMCID: PMC2588932     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  82 in total

1.  [A simple operation for control of reflux esophagitis].

Authors:  R NISSEN
Journal:  Schweiz Med Wochenschr       Date:  1956-05-18

2.  A long-term randomized prospective trial of the Nissen procedure versus a modified Toupet technique.

Authors:  K B Thor; T Silander
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

3.  Reflux esophagitis, sliding hiatal hernia, and the anatomy of repair.

Authors:  P R ALLISON
Journal:  Surg Gynecol Obstet       Date:  1951-04

4.  Hiatus hernia: (a 20-year retrospective survey).

Authors:  P R Allison
Journal:  Ann Surg       Date:  1973-09       Impact factor: 12.969

5.  Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux.

Authors:  H J Stein; A P Barlow; T R DeMeester; R A Hinder
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

6.  Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group.

Authors:  S J Spechler
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

7.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

8.  Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment.

Authors:  E Solcia; R Fiocca; N Havu; A Dalväg; R Carlsson
Journal:  Digestion       Date:  1992       Impact factor: 3.216

9.  Role of the components of the gastroduodenal contents in experimental acid esophagitis.

Authors:  K D Lillemoe; L F Johnson; J W Harmon
Journal:  Surgery       Date:  1982-08       Impact factor: 3.982

10.  Lower esophageal sphincter characteristics and esophageal acid exposure following partial or 360 degrees fundoplication: results of a prospective, randomized, clinical study.

Authors:  L Lundell; H Abrahamsson; M Ruth; N Sandberg; L C Olbe
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

View more
  4 in total

1.  Quality of life in GERD patients: medical treatment versus antireflux surgery.

Authors:  Ruxandra Ciovica; Michael Gadenstätter; Anton Klingler; Wolfgang Lechner; Otto Riedl; Gerhard P Schwab
Journal:  J Gastrointest Surg       Date:  2006 Jul-Aug       Impact factor: 3.452

2.  Preoperative lower esophageal sphincter manometry data neither impact manifestations of GERD nor outcome after laparoscopic Nissen fundoplication.

Authors:  Otto Riedl; Michael Gadenstätter; Wolfgang Lechner; Gerhard Schwab; Martina Marker; Ruxandra Ciovica
Journal:  J Gastrointest Surg       Date:  2009-04-16       Impact factor: 3.452

3.  The use of medication after laparoscopic antireflux surgery.

Authors:  Ruxandra Ciovica; Otto Riedl; Christoph Neumayer; Wolfgang Lechner; Gerhard P Schwab; Michael Gadenstätter
Journal:  Surg Endosc       Date:  2009-01-24       Impact factor: 4.584

4.  Evaluation of resection of the gastroesophageal junction and jejunal interposition (Merendino procedure) as a rescue procedure in patients with a failed redo antireflux procedure. A single-center experience.

Authors:  Apostolos Analatos; Mats Lindblad; Ioannis Rouvelas; Peter Elbe; Lars Lundell; Magnus Nilsson; Andrianos Tsekrekos; Jon A Tsai
Journal:  BMC Surg       Date:  2018-08-30       Impact factor: 2.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.